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Abstract
Clinical response to immunotherapy is closely associated with the immunosuppressive tumour microenvironment (TME), and
influenced by the dynamic interaction between tumour cells and lymphatic endothelial cells (LECs). Here, we show that high
levels of miR-142-5p positively correlate with indoleamine 2,3-dioxygenase (IDO) expression in tumour-associated lymphatic
vessels in advanced cervical squamous cell carcinoma (CSCC). The miR-142-5p is transferred by CSCC-secreted exosomes into
LECs to exhaust CD8+ T cells via the up-regulation of lymphatic IDO expression, which was abrogated by an IDO inhibitor.
Mechanistically, miR-142-5p directly down-regulates lymphatic AT-rich interactive domain-containing protein 2 (ARID2)
expression, inhibits DNA methyltransferase 1 (DNMT1) recruitment to interferon (IFN)-γ promoter, and enhances IFN-γ
transcription by suppressing promoter methylation, thereby leading to elevated IDO activity. Furthermore, increased serum
exosomal miR-142-5p levels and the consequent IDO activity positively correlate with CSCC progression. In conclusion,
exosomes secreted by CSCC cells deliver miR-142-5p to LECs and induce IDO expression via ARID2–DNMT1–IFN-γ
signalling to suppress and exhaust CD8+ T cells. Our study suggests that LECs act as an integral component of the immune
checkpoint(s) in the TME and may serve as a potential new target for CSCC diagnosis and treatment.
Introduction
Tumour progression has been considered as a consequence of
the evolving crosstalk between different cell types within the
tumour and its stroma [1–3]. The remodelling of regional
lymphatic vessels (LVs) conferred by tumour cells is asso-
ciated with enhanced malignant progression and poor out-
come in many solid tumours, including cervical squamous
cell carcinoma (CSCC) [2]. Besides offering physical routes
for metastatic spread [4, 5], tumour-associated LVs are
thought to be involved in the modulation of adaptive immune
responses [6]. These findings have focused research attention
on tumour-associated lymphatic endothelial cells (LECs), one
of many types of stromal cells, that help establish an immu-
nosuppressive tumour microenvironment (TME), which pro-
motes the evasion of anti-tumour immunity. A better
understanding of the immunosuppressive mechanisms of
tumour-associated LECs would thus facilitate the rational
development of therapeutic strategies.
The recent discovery of miRNAs and their extracellular
presence have highlighted the potential role of these regulatory
molecules in mediating the cancer-stroma crosstalk [7]. In the
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extracellular space, miRNAs either bind to proteins or lipids
[8] or serve as a major RNA component of exosomes [9].
Exosomes are small 30–150 nm membrane vesicles that are
delivered into the extracellular environment by different cell
types, including cancer cells [1]. These exosomes reflect the
expression patterns of dysregulated miRNAs in cancer cells.
Thus, cancer-secreted exosomes may deliver miRNAs to host
recipient cells to modify gene expression on a genome-wide
scale. The expression of the miR-142-5p that serves as a
tumour suppressor has been reported to be down-regulated in
gastric cancer [10], while it is up-regulated as a strong
oncogene in cutaneous squamous cell carcinoma, colorectal
cancer, and renal cell carcinoma [11–13]. However, there are
no reports on the cancer-derived exosomal miR-142-5p that
may shape the cancer immune landscape and create immune
checkpoint(s) in the TME.
Indoleamine 2,3-dioxygenase (IDO) is an intercellular
enzyme that converts the essential amino acid tryptophan
into kynurenine through the IDO/kynurenine pathway [14].
IDO activity is monitored by measuring kynurenine to
tryptophan (K:T) ratio [15]. Elevated IDO activity corre-
lates with a decrease in the population of tumour-infiltrating
lymphocytes (TILs) in oesophageal and endometrial cancers
[16, 17] and poor clinical outcomes in multiple types of
cancers [18–20]. These clinical observations support the
paradigm that IDO contributes to immune checkpoint
development and promotes tumour progression by attenu-
ating effector T cell responses. Although IDO may be
expressed by tumour, stroma, and immune cells in the TME
[21, 22], little is known about the molecular mechanism and
function of IDO in tumour-associated LVs.
Here, we investigated whether cancer-secreted exosomal
miR-142-5p modulates the tumour immune status of CSCC
by inducing IDO expression and evaluated the molecular
mechanism underlying miR-142-5p-mediated tumour pro-
gression to reveal the potential clinical applications of this
miRNA in the diagnosis and therapy of CSCC.
Materials and methods
Cell lines
The human CSCC cell lines Siha, Caski, C33A, ME180,
and MS751 were purchased from the American Type Cul-
ture Collection (ATCC) and cultured as per the guidelines.
Human dermal lymphatic endothelial cells (HDLECs; IDO-
negative) were obtained from ScienCell and cultured in
endothelial cell medium (ECM; ScienCell) supplemented
with 10% foetal bovine serum (FBS; Gibco) and endothelial
growth medium supplements (ScienCell). In all related
experiments, CSCC cell lines and HDLECs were used
within 20 and 6 passages, respectively.
Clinical samples
CSCC tissue microarrays were purchased from SHANGHAI
OUTDO BIOTECH CO., LTD. Blood samples were obtained
from voluntarily CSCC patients without preoperative radio-
therapy or chemotherapy at the department of Gynaecological
Oncology of the First Affiliated Hospital of Guangzhou
Medical University (Guangzhou, China) or healthy donors
between 2016 and 2017. The human study was approved by
the World Medical Association Declaration of Helsinki and
Institutional Research Ethics Committee at Ministry of Public
Health of PR China. Written informed consent was obtained
from all patients or healthy donors. All blood samples were
centrifuged at 2500 × g for 10min to extract serum. All
samples were stored at –80 °C until further study.
Exosome isolation, characterisation, and treatment
Exosomes were purified from CSCC-derived supernatant or
the serum of CSCC patients by ultracentrifugation. Cell cul-
ture supernatants were collected after 48 h and centrifuged at
500 × g for 10 min at 4 °C and then at 10,000 × g for 30min
at 4 °C. The serum was diluted with an equal volume of
phosphate-buffered saline (PBS) and centrifuged at 2000 × g
for 30min at 4 °C, followed by 12,000 × g for 45min at 4 °C.
The supernatants were then passed through 0.22 µm filters
(Millipore) and ultra-centrifuged at 100,000 × g for 70min at
4 °C. The exosome pellets were washed with PBS and sub-
jected to a second ultracentrifugation step at 100,000 × g for
70 min at 4 °C and then resuspended in PBS. The exosomes
were evaluated by Nanosight NS300 (Malvern). For trans-
mission electron microscopy, exosomes were fixed with 2%
glutaraldehyde and loaded on carbon-coated grids. The grids
were then subjected to negative staining using phospho-
tungstic acid for 2 min and visualised by transmission electron
microscopy (Hitachi H-7500). For the exosome uptake study,
PKH67 membrane dye (Sigma) was added to PBS at 1 µM
concentration and incubated with exosomes for 20min before
washing. The excess dye was removed by an additional
washing step, and the labelled exosomes were resuspended
and used to treat HDLECs. After a 48-h incubation, HDLECs
were labelled with phalloidin for confocal imaging. For
treatment of cells and animals, 2 µg exosomes, as measured
using a bicinchoninic acid (BCA) protein assay kit (Beyo-
time), were added to 1 × 105 recipient cells for 48 h.
Real-time quantitative polymerase chain reaction
(RT-qPCR)
The RNA was extracted from cells and exosomes using the
miRNeasy Mini Kit (Qiagen) according to the manu-
facturer’s instructions. Reverse transcription was performed
using the Mir-X™ miRNA First-Strand Synthesis Kit
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(TaKaRa) for miRNAs or PrimeScript™ RT Master Mix
(TaKaRa) for general genes. RT-qPCR was conducted
using SYBR Premix Ex Taq™ (TaKaRa) on an Applied
Biosystems 7500 Fast Real-Time PCR System (Applied
Biosystems). Specific primer sets for miR-142-5p and U6
were obtained from RiboBio Inc. The expression of miR-
NAs and mRNAs was normalised to U6 and GAPDH,
respectively. The primer sequences are shown in Supple-
mentary Table S1.
Western blot analysis
Cell and exosome lysates were prepared in radio-
immunoprecipitation assay (RIPA) buffer (FUDE BioTech)
and quantified using Bradford protein assay (Beyotime).
The lysates were subjected to sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and the
separated protein bands were transferred onto poly-
vinylidene fluoride membranes (Millipore). The membranes
were incubated with primary antibodies for overnight at
4 °C, and then probed with a specific horseradish
peroxidase (HRP)-conjugated anti-rabbit or anti-mouse
immunoglobulin-G antibody (ab6721 or ab6728, Abcam).
The chemiluminescence signal was detected using the
FD8020 FDbio-Dura ECL Kit (FUDE BioTech). The pri-
mary antibodies used in this study are shown in Supple-
mentary Table S2.
Fluorescence in situ hybridisation (FISH) and
immunohistochemistry (IHC)
FISH was performed on CSCC tissue microarrays using a
fluorescence ISH kit (Boster BioTech) and the miR-142-5p
synthetic oligonucleotide probes (Exiqon), according to the
manufacturer’s protocol. In brief, the slides were incubated
with 3% hydrogen peroxide (H2O2), digested with pepsin
for 2 min at 37 °C, and fixed with 1% paraformaldehyde
(PFA) in diethyl pyrocarbonate (DEPC) for 5 min. The
slides were then pre-hybridised in a hybridisation buffer at
42 °C with miR-142-5p or U6 probes and incubated with
fluorescent streptavidin-biotin complex (f-SABC) and
horseradish peroxidase polymer. For IHC, sections were
immersed in 3% H2O2 to block endogenous peroxidase
activity and incubated with primary antibodies, overnight at
4 °C. A horseradish peroxidase-conjugated anti-rabbit sec-
ondary antibody (ZSGB BioTech) was subsequently
applied for 1 h at room temperature. The expression of
D240 (M361929-2, DAKO), IDO (86630, CST), and CD8
(ab93278, Abcam) was visualised using 3,3′-diamino-
benzidine (DAB) following counterstaining with haema-
toxylin (ZSGB BioTech). FISH- and IHC-stained tissue
sections were reviewed and scored separately by two
independent pathologists. For semi-quantitative evaluation
of IDO and miR-142-5p expression in tissue sections, the
German Immuno-Reactive Score was applied as previously
described [23].
Multiplexed immunofluorescence staining
Multiplexed immunofluorescence staining was performed
by OPAL 4-colour fluorescence IHC Kit (Perkin Elmer)
according to manufacturer’s protocol. The following pri-
mary antibodies were used: D240 (M361929-2, DAKO)
and IDO (86630, CST). After deparaffinization, steps
were repeated for each primary antibody and sections
were microwaved in an antigen retrieval buffer for 45 s at
100 °C. The slides were washed and blocked for 10 min at
room temperature, and then incubated with a primary
antibody. Next, slides were incubated with SuperPicture
Polymer Detection Kit-HRP-broad spectrum (Life Tech-
nologies), and subsequently treated with Opal fluor-
ochromes (Opal520 and Opal570) diluted 1:150 in an
amplification buffer (all provided by the OPAL 4-colour
fluorescence IHC kit) for 10 min at room temperature.
Finally, a microwave treatment with AR6 buffer was
performed. The slides were then incubated with a 4′,6-
diamidino-2-phenylindole (DAPI) working solution
(provided by the OPAL 4-colour fluorescence IHC kit) for
5 min at room temperature and then mounted under cov-
erslips with ProLong Diamond Antifade Mountant (Life
Technologies).
Stable transfection with lentiviral vector
Lenti-GFP containing an miR-142-5p overexpression
sequence and its negative control RNA (miR-NC) were all
purchased from GeneChem Inc. Siha and Caski cells were
transfected with lenti-GFP/miR-142-5p or lenti-GFP/miR-
NC. Polyclonal cells with green fluorescent protein signals
were purified for further experiments using a fluorescence-
activated cell sorting flow cytometer.
Transient transfection with oligonucleotides and
plasmids
The miR-142-5p mimics and their negative control (miR-
NC) were designed and cloned by RiboBio Inc. The ARID2
coding sequence (without 3’-UTR) was cloned into the
pCDNA3.1(+)-Vector (Invitrogen). The empty vector was
used as a blank control. SiARID2 and its negative control
(siRNA) were designed and synthesised by GenePharma
Inc. Lipofectamine 2000 Reagent (Invitrogen) was then
used to transfect miR-142-5p mimics or inhibitors,
siARID2, and pCDNA3.1(+)-ARID2 according to the
manufacturer’s protocol. For RNA extraction, western blot
and in vitro assays, cells were used 48 h after transfection.
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The sequences of siARID2 and siRNA are shown in Sup-
plementary Table S1.
In vivo xenograft model
Female B-NDG® (NOD- PrkdcscidIL2rgtm1/Bcgen) mice (5-
weeks-old) were purchased from Beijing Biocytogen Co.,
Ltd. Siha or Caski cells (1 × 105) mixed with conditioned
HDLECs (1 × 105) treated with miR-142-5p mimics or
exosomes from Siha/miR-142-5p or Caski/miR-142-5p
were randomly injected into the right flank of each mouse
(n= 6 per group). The tumours were harvested for analysis
after 15 days. All animal studies were approved by the
Institutional Animal Research Ethics Committee of
Guangzhou Medical University.
Human-activated CD8+ T cell preparation
Peripheral blood mononuclear cells (PBMCs) were isolated
from healthy donors using Ficoll-Paque Plus (GE Health-
care). CD8+ T cells were isolated from PBMCs by magnetic
bead purification using a human CD8+ T cell enrichment kit
(STEMCELL Technologies). The purity (> 95%) was
evaluated by flow cytometry using an eF450-labelled anti-
body against CD8 (48–0087–42, Thermo Fisher). CD8+
T cells were cultured in complete Roswell Park Memorial
Institute (RPMI)-1640 medium. Then, CD8+ T cells (1 ×
105) were activated by stimulation with plate-bound anti-
CD3 (OKT3, Thermo Fisher) at 2.5 µg/mL and anti-CD28
(10F3, Thermo Fisher) at 2 µg/mL in vitro.
In vitro CD8+ T cell immune suppression
HDLECs (1 × 105) treated as indicated with or without
100 µM BMS-986205 (HY-101560, MCE) were co-
cultured with activated CD8+ T cells (1 × 105) in the pre-
sence of a semipermeable transwell membrane (BD
Biosciences). To access the cytotoxic activity of CD8+
T cells, the cells from 3-day co-cultures were subjected to
surface or intracellular staining using the following anti-
human antibodies or controls: fluorescein isothiocyanate
(FITC)-conjugated anti-CD69 (11–0699–42, Thermo
Fisher), phycoerythrin (PE)-conjugated anti-interferon
(IFN)-γ (12–7319–42, Thermo Fisher), allophycocyanin
(APC)-conjugated anti-programmed cell death protein-1
(PD-1; 17–2799–42, Thermo Fisher), or a fluorochrome-
conjugated control IgG isotype. For analysis of CD8+ T cell
apoptosis, the proportion of apoptotic CD8+ T cells was
examined using an annexin V-APC apoptosis detection kit
(KGF004, KeyGEN Biotech) after 7 days of co-cultures.
Flow cytometry was performed using FACS LSRFortessa
(BD Biosciences), and data were analysed with FlowJo VX
software.
Measurements of tryptophan and kynurenine
Supernatant or serum levels of tryptophan and kynurenine
were measured using high-performance liquid chromato-
graphy (HPLC; UltiMate 3000, Thermo Fisher), as pre-
viously described with minor modifications [15]. For
supernatants, 100 µL samples were diluted with a 1/10
volume of 150 mM NaAc (pH 4.0) and deproteinated with
perchloric acid. For serum samples, 100 µL samples were
diluted with an equal volume of 30 mM NaAc (pH 4.0) and
deproteinated with 10% trichloric acid. In total, 50 µL of
diluted samples were then loaded and analysed on a C18
column (Thermo Fisher). Tryptophan and kynurenine were
detected on a UV channel at 280 and 360 nm, respectively.
Samples were analysed using Dionex™ Chromeleon™
7.0 software (Thermo Fisher) and quantified using external
standards. At least one quality control sample was randomly
inserted into every plate for reference. All assays were
performed in triplicates, and each experiment was repeated
thrice.
Chromatin immunoprecipitation (ChIP) assay
Cells were crosslinked with 1% formaldehyde, quenched
in a glycine solution, and subjected to CHIP assay using
an enzymatic chromatin IP kit (#9003, CST) according to
the manufacturer’s protocol. Anti-AT-rich interactive
domain-containing protein 2 (ARID2) (orb386710, Bio-
byt), anti-DNA methyltransferase 1 (DNMT1) (61467,
active motif), and normal IgG (Millipore) antibodies
were used for immunoprecipitation. ChIP-enriched
DNA samples were quantified by qPCR to determine
ARID2- and DNMT1-binding sites in the IFN-γ promoter
region. Data were shown as relative enrichment
following normalisation to control IgG. The primer
sequences used for ChIP-qPCR are shown in Supple-
mentary Table S1.
Methylation-specific polymerase chain reaction
(MSP)
MSP was performed according to a previous study [24]
using methylated primer pairs designed from the free online
tool, MethPrimer (http://www.urogene.org/methprimer/
index1.html). The methylated (M) and unmethylated
(UM) primer sequences are shown in Supplementary
Table S1.
Other methods
Staining assessment, Luciferase activity assay, and ELISA
assay were performed using the manufacturer’s protocol.
See Supplementary Methods for more details.
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Statistical analysis
SPSS V.13.0 software was used for statistical analysis.
Quantitative values in all experiments are expressed as the
means ± standard deviation (SD). A two-tailed Student’s t
test or one-way analysis of variance (ANOVA) was used
for comparison between multiple groups. The Fisher or chi-
square-test was applied for categorical variables. Correla-
tion analysis was performed using the Spearman rank
test. Differences were considered statistically significant at
P < 0.05.
Results
miR-142-5p expression during CSCC progression
correlates with lymphatic IDO expression and is
negatively associated with the number of
infiltrating CD8+ T cells
To evaluate the expression of miR-142-5p during CSCC
progression, we analysed 116 human CSCC tissue micro-
arrays using ISH. Compared with those in early stages
(FIGO 2018, stages I and II, n= 93), miR-142-5p
expression and the ratios of peritumoral IDO+ LVs indi-
cated by both IDO- and D240-positive vessels were sig-
nificantly higher in advanced stage CSCC patients (FIGO
2018, stages III and IV, n= 23), whereas the number of
CD8+ T cells decreased during CSCC progression
(Fig. 1a–d). Thus, miR-142-5p expression positively cor-
related with the ratio of peri-tumoural IDO+ LVs to total
LVs (Fig. 1e). Further, miR-142-5p expression and the ratio
of peri-tumoural IDO+ LVs to total LVs were negatively
associated with the number of tumour-infiltrating CD8+
T cells (Fig. 1f, g). As shown in Fig. 1a, high lymphatic
miR-142-5p and IDO expression co-localised with high
miR-142-5p expression in the tumour, indicating that the
tumour-derived miR-142-5p transferred to peri-tumoural
LVs may up-regulate lymphatic IDO expression.
miR-142-5p can be transferred to HDLECs via CSCC-
secreted exosomes
Several recent studies have shown that cancer-secreted
exosomal miRNAs regulate the crosstalk between malig-
nant and stromal cells in the TME [25]. We, therefore,
investigated whether miR-142-5p is involved in the cross-
talk between CSCC cells and HDLECs through exosomes.
Fig. 1 miR-142-5p expression correlates with lymphatic IDO
expression and is negatively associated with the number of infil-
trating CD8+ T cells during CSCC progression. a Representative
micrographs of miR-142-5p, IDO, and D240 (lymphatic marker)
staining in serial sections of CSCC specimens are shown. The LVs are
indicated by red arrows. The tumour cells are indicated by black
arrows. Scale bar: 50 µm. b–d ISH scores (Hscore) of miR-142-5p,
ratio of IDO+ LVs to total LVs, and number of CD8+ T cells per field
were analysed in serial sections from early-stage (FIGO 2018, stages I
and II, n= 93) and advanced-stage (FIGO 2018, stages III and IV, n=
23) CSCC patients. e–g Correlation between miR-142-5p level, ratio
of IDO+ LVs to total LVs, and number of CD8+ T cells was analysed.
miR-142, miR-142-5p. Error bars represent the mean ± SD of three
independent experiments. ***P < 0.001.
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Evaluation of all CSCC cell lines for of miR-142-5p
expression showed that the level of miR-142-5p in Siha and
Caski cells was similar to that observed in stage I tumour
tissues but significantly lower than that reported in stage III
tumour tissues (Supplementary Fig. S1a). Then, a lentiviral
vector expressing miR-142-5p or negative control (NC) was
successfully constructed and transfected into Siha and Caski
cells (Supplementary Fig. S1b). Next, exosomes were iso-
lated and purified from cell culture supernatants using
standard ultracentrifugation. The cup-shaped structure, size,
and number of isolated exosomes were identified by trans-
mission electron microscopy and Nanosight particle track-
ing analysis (Fig. 2a, b). The isolated particles were
confirmed to be exosomes through the characteristic
expression of CD9, heat shock protein 70 (HSP70), and
tumour susceptibility 101 (TSG101) (Fig. 2c). To evaluate
the delivery of exosomes, the CSCC-secreted exosomes and
HDLECs were labelled with PKH67 (green) and phalloidin
(red), respectively. After 48 h incubation, confocal imaging
was performed that revealed the appearance of green
fluorescent spots in recipient HDLECs, indicating that the
labelled exosomes secreted by CSCC cells were delivered to
HDLECs (Fig. 2d).
RT-qPCR analysis showed a significant increase in the
expression of miR-142-5p in the exosomes secreted by
lenti-miR-142-5p-transfected Siha and Caski cells as com-
pared with that in NC (Fig. 2e). To investigate whether the
CSCC-secreted miR-142-5p is transferred to HDLECs via
exosomes, we detected miR-142-5p level in HDLECs
incubated with CSCC-secreted exosomes. The expression
of miR-142-5p was higher in HDLECs incubated with
exosomes with high miR-142-5p level than in HDLECs
Fig. 2 miR-142-5p can be transferred to human dermal lymphatic
endothelial cells (HDLECs) via CSCC-secreted exosomes. a and
b The morphology and size of exosomes secreted by Siha and Caski
cells transfected with lentivectors overexpressing miR-142-5p or NC
were confirmed by transmission electron microscopy and Nanosight
particle tracking analysis. Scale bar, 50 nm. c Characteristic marker
expression (CD9, HSP70, and TSG101) of exosomes was confirmed
by western blotting. d Confocal imaging showed the delivery of
PKH67-labelled exosomes (green) to phalloidin-labelled HDLECs
(red). Scale bar, 25 µm. e miR-142-5p levels in indicated exosomes
were detected by RT-qPCR. f miR-142-5p levels in HDLECs pre-
treated with PBS or indicated exosomes for 24 h were detected by RT-
qPCR. S/miR-NC exo Siha/miR-NC exosomes, S/miR-142 exo Siha/
miR-142-5p exosomes, C/miR-NC exo Caski/miR-NC exosomes,
C/miR-142 exo Caski/miR-142-5p exosomes. Error bars represent the
mean ± SD of three independent experiments. ***P < 0.001.
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incubated with exosomes with low miR-142-5p (Fig. 2f),
indicating the horizontal transfer of miRNA-142-5p from
CSCC cells to HDLECs via exosomes.
CSCC-secreted exosomal miR-142-5p up-regulates
lymphatic IDO expression
To investigate the biological role of exosomal miR-142-5p in
mediating lymphatic expression of IDO, we analysed the
expression of IDO in HDLECs incubated with CSCC-secreted
exosomes for 48 h by western blotting. IDO expression was
significantly up-regulated in HDLECs treated with miR-142-
5p mimics or exosomes containing miR-142-5p as compared
with that in NC (Fig. 3a). As IDO enzyme degrades trypto-
phan and generates the tryptophan catabolite kynurenine [15],
we assessed the concentrations of tryptophan and kynurenine
in culture media using HPLC. An increase in kynurenine to
tryptophan (K:T) ratio, indicative of elevated IDO activity,
was observed in the supernatant of HDLECs treated with miR-
142-5p mimics or exosomes containing miR-142-5p, but not
in NC samples (Fig. 3b), consistent with the observation of
IDO protein level.
To assess the role of exosomal miR-142-5p in the
remodelling of the lymphatic phenotype in vivo, Siha cells
mixed with conditioned HDLECs treated with exosomes
from Siha/miR-142-5p or miR-142-5p mimics were sub-
cutaneously injected into the right flanks of mice (n= 6 per
group). After 15 days, the Siha cell group showed higher
lymphatic expression of miR-142-5p and IDO (Fig. 3c–e)
and serum K:T ratio (Fig. 3f) compared to the control
group. Similar results were observed for the group exposed
to Caski cells mixed with conditioned HDLECs treated with
exosomes from Caski/miR-142-5p or miR-142-5p mimics
(Supplementary Fig. S2a–d). In addition, HDLECs mixed
with Siha/miR-NC, Siha/miR-142-5p, Caski/miR-NC, or
Caski/miR-142-5p were used to construct the above xeno-
graft model. The lymphatic expression of miR-142-5p and
IDO (Supplementary Fig. S3a–c) and the serum K:T ratio
(Supplementary Fig. S3d) were higher in the group of
HDLECs mixed with Siha/miR-142-5p or Caski/miR-142-
5p than in the group mixed with Siha/miR-NC or Caski/
miR-NC. Taken together, CSCC-secreted exosomal miR-
142-5p up-regulates the lymphatic expression of IDO
in vitro and in vivo.
CSCC-secreted exosomal miR-142-5p directly targets
ARID2 in HDLECs
Three bioinformatic tools (miRWalk, miRDB, and miRT-
CDS) were employed to identify the candidate targets of miR-
142-5p. All three programs predicted CCNT2, RAP1A,
ARID2, ITGAV, FIGN, and FAM199X as candidate targets of
miR-142-5p. To verify these predictions, we performed RT-
qPCR analyses and found that only ARID2 expression was
significantly down-regulated in HDLECs following pre-
treatment with miR-142-5p mimics (Fig. 4a). We also con-
firmed the decrease in the protein level of ARID2 in HDLECs
treated with miR-142-5p mimics or exosomes containing
miR-142-5p (Fig. 4b). We then determined the alignment
between miR-142-5p and full-length ARID2 sequences and
found an ARID2-coding sequence as a potential target of
miR-142-5p (Fig. 4c). The wild-type and mutated miR-142-
5p-binding sites were cloned into luciferase vectors and the
luciferase activity was found to be significantly decreased in
HDLECs co-transfected with the vector carrying the wild-
type-binding site in the presence of miR-142-5p mimics, but
not in HDLECs carrying the mutated-binding site (Fig. 4d).
The protein level of ARID2 and luciferase activity also dra-
matically decreased in HDLECs treated with exosomes con-
taining miR-142-5p (Fig. 4e, f). In addition, ARID2
expression level was examined in 116 human CSCC tissue
microarrays using IHC and found to be significantly lower in
advanced-stage (FIGO 2018, stages III and IV, n= 23) CSCC
patients than in early-stage CSCC patients (FIGO 2018,
stages I and II, n= 93) (Supplementary Fig. S4a). Further,
ARID2 expression negatively correlated with miR-142-5p
level in human CSCC tissues (Supplementary Fig. S4b).
Taken together, these results suggest that ARID2 is a direct
target of miR-142-5p.
We transfected cells with a plasmid-overexpressing
ARID2 without 3′-untranslated region (UTR) or a specific
small-interfering RNA (siRNA) SiARID2 that suppressed
the expression of ARID2. Western blot analysis confirmed
that plasmid-ARID2 and SiARID2 effectively over-
expressed and knocked down ARID2 expression in
HDLECs, respectively (Fig. 4g). Further in vitro studies
confirmed that ARID2 overexpression neutralised the abil-
ity of miR-142-5p mimics or exosomes containing miR-
142-5p to induce IDO activity (Fig. 4g, h). In contrast,
ARID2 knockdown replicated the effects of miR-142-5p
overexpression in HDLECs by inducing functional IDO
expression (Fig. 4g, h). As IFN-γ induces IDO expression
[26, 27], we next assessed whether IFN-γ expression was
induced by the miR-142-5p-ARID2 axis. miR-142-5p
overexpression or ARID2 knockdown significantly up-
regulated the lymphatic level of IFN-γ, whereas ARID2
overexpression decreased the up-regulated level of IFN-γ
induced by miR-142-5p mimics or exosomes containing
miR-142-5p (Fig. 4i).
ARID2 recruits DNMT1 to the IFN-γ promoter and
enhances its methylation
As ARID2 mediated the expression of IFN-γ, we explored
whether there exists a direct link between ARID2 and IFN-γ.
As shown in Fig. 5a, luciferase reporter assay revealed the
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increase and decrease in IFN-γ promoter-driven luciferase
activity in ARID2-silenced and ARID2-overexpressing cells,
respectively. To investigate the role of ARID2 in IFN-γ
expression, a ChIP-PCR assay was performed to determine
whether the IFN-γ promoter region (from −1 to −1000 bp
upstream of the exon) was occupied by ARID2. We found
only one binding site (−201 to −360 bp) that showed strong
interaction with ARID2 in HDLECs (Fig. 5b). Thus, ARID2
directly suppresses the transcription of IFN-γ.
As a subunit of the polybromo-associated BAF (PBAF)
complex, ARID2 potentially interacts with epigenetic reg-
ulators and modulates gene transcription [28]. A recent
study reported that DNMT1 was recruited as an epigenetic
modulator by ARID2 to enhance the methylation of Snail
promoter [29]. This observation promoted us to investigate
the involvement of the ARID2-DNMT1 complex in the
regulation of IFN-γ transcription. ChIP-RE-CHIP assay
result suggests that DNMT1 and ARID2 co-occupied the
Fig. 3 CSCC-secreted exosomal miR-142-5p up-regulates lym-
phatic IDO expression. a Protein level of IDO was detected in
HDLECs pre-treated with miR-142-5p mimics or indicated exosomes
by western blotting and compared with that in the control group. b The
ratio of kynurenine to tryptophan (K:T) in the supernatant of HDLECs
(1 × 105 cells) after indicated treatment was calculated. c Representa-
tive micrographs of miR-142-5p, IDO, and D240 immunofluorescence
staining in sections of xenograft tumours are shown. Scale bar: 50 µm.
d–f The lymphatic expression of miR-142-5 and IDO and serum
kynurenine to tryptophan (K:T) ratio in each group were calculated.
S/miR-NC Siha/miR-NC, S/miR-142 Siha/miR-142-5p, C/miR-NC
Caski/miR-NC, C/miR-142 Caski/miR-142-5p, exo exosomes.
Error bars represent the mean ± SD of three independent experiments.
***P < 0.001.
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same promoter region of IFN-γ (Fig. 5c). Further, the
binding of DNMT1 to the IFN-γ promoter increased
in ARID2-overexpressing HDLECs and decreased in
ARID2-silenced cells, suggesting that ARID2 recruited
DNMT1 to the IFN-γ promoter (Fig. 5d). We also found
that the CpG island (−153 to −277 bp) overlapped with the
Fig. 4 CSCC-secreted
exosomal miR-142-5p directly
targets ARID2 in HDLECs.
a Overlap of three miRNA target
bioinformatic prediction
algorithms. The expression of
CCNT2, RAP1A, ARID2,
ITGAV, FIGN, and FAM199X in
HDLECs pre-treated with miR-
142-5p mimics or NC was
detected by RT-qPCR. b The
protein level of ARID2 in
HDLECs pre-treated with miR-
142-5p mimics or NC was
analysed by western blotting.
c The wild-type- and mutated-
binding sites between miR-142-
5p and ARID2 were shown.
d Relative luciferase activity of
HDLECs pre-treated with miR-
142-5p mimics or NC was
analysed. e The protein level of
ARID2 in HDLECs pre-treated
with indicated exosomes was
analysed by western blotting.
f Relative luciferase activity of
HDLECs pre-treated with
indicated exosomes was
analysed. g The expression of
ARID2 and IDO proteins in
miR-142-5p-mimic/exosome-
treated HDLECs transfected
with plasmid-ARID2 or vector
control and SiARID2- or
SiRNA-treated HDLECs was
detected by western blotting.
h The K:T ratio of HDLEC
supernatant after the indicated
treatment was calculated. i IFN-
γ protein level in the supernatant
of HDLECs following indicated
treatment was detected by
ELISA. miR-142, miR-142-5p.
S/miR-142 Siha/miR-142-5p,
C/miR-NC Caski/miR-NC, C/
miR-142 Caski/miR-142-5p,
exo exosomes, WT wild-type,
MT mutant. Error bars represent
the mean ± SD of three
independent experiments. *P <
0.05; **P < 0.01; ***P < 0.001.
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binding site of the ARID2-DNMT1 complex at the IFN-γ
promoter (−201 to −360 bp) (Fig. 5e). MSP assay result
showed the up-regulation and down-regulation in IFN-γ
promoter methylation in ARID2-overexpressing and
ARID2-silenced HDLECs, respectively, following DNMT1
binding (Fig. 5f). Taken together, our results show that
ARID2 suppressed the transcription of IFN-γ by recruiting
DNMT1 to IFN-γ promoter, thereby elevating promoter
methylation in HDLECs.
miR-142-5p-activated HDLECs induce IDO
expression to exhaust CD8+ T cells
IDO promotes immune suppression through the attenua-
tion of CD8+ T cell response [30]. To test whether
HDLECs exposed to miR-142-5p contribute to
suppressive effects on CD8+ T cell immunity, HDLECs
pre-treated with exosomes with miR-142-5p or miR-142-
5p mimics were co-cultured with in vitro-activated CD8+
T cells in the presence of a semipermeable transwell
membrane. The CD8+ T cells were collected for flow
cytometric analysis after culture. HDLECs pre-treated
with exosomes containing miR-142-5p showed lower
percentages of CD69+ (activated) and IFN-γ+ CD8+
(effector) T cells compared to the control cells (Fig. 6a, b)
and had higher percentages of PD-1+ (inhibitory) and
annexin V+ (apoptotic) CD8+ T cells (Fig. 6c, d). The
blockade of IDO or miR-142-5p in HDLECs with an IDO
inhibitor (BMS-986205) or miR-142-5p inhibitor (anti-
142-5p) treatment, respectively, reversed the suppressive
effects on CD8+ T cell functions induced by HDLECs
pre-treated with exosomes containing high levels of
Fig. 5 ARID2 enhances the methylation of IFN-γ promoter by
recruiting DNMT1. a Relative luciferase activity of IFN-γ promoter
in HDLECs following ARID2 overexpression or knockdown. b ChIP
assay for the enrichment of ARID2 in the promoter region of IFN-γ in
HDLECs. c ChIP-Re-ChIP assay to determine ARID2-DNMT1 co-
occupancy in the promoter region of IFN-γ. d ChIP assay for the
enrichment of DNMT1 in the promoter region of IFN-γ in HDLECs
following ARID2 overexpression or knockdown. e Schematic map of
the CpG island region in the IFN-γ promoter. f MSP assay to detect the
methylation level of the IFN-γ promoter in HDLECs following ARID2
overexpression or knockdown. Error bars represent the mean ± SD of
three independent experiments. ***P < 0.001.
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miR-142-5p (Fig. 6a–d; Supplementary Fig. S5a–d).
Likewise, HDLECs treated with miR-142-5p mimics also
showed a decrease in the percentages of CD69+ and
IFN-γ+ CD8+ T cells along with an increase in the per-
centages of PD-1+ and annexin V+ CD8+ T cells; these
phenomena were reversed after IDO blockade
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(Supplementary Fig. S6a–d). Thus, IDO contributes to the
immune suppression mediated by miR-142-5p-exposed
HDLECs.
Serum exosomal miR-142-5p levels correlate with
systemic IDO activity and clinicopathological
progression in patients with CSCC
To investigate whether the cancer-secreted miR-142-5p
could be detected in the serum of CSCC patients, the exo-
somes were isolated from the serum of early-stage (FIGO
2018, stages I and II, n= 27) and advanced-stage (FIGO
2018, stages III and IV, n= 17) CSCC patients as well as
healthy controls (n= 8) and characterised. The typical
morphology and size range of the exosomes purified from
the serum were consistent with those of the exosomes
derived from cell culture supernatants (Fig. 7a). We then
examined exosomal miR-142-5p from these serum samples.
As shown in Fig. 7b, the serum exosomal miR-142-5p
levels were higher in CSCC patients than in healthy con-
trols. miR-142-5p levels were higher in the serum exosomes
from advanced-stage CSCC patients than in those from
early-stage CSSC patients. The serum K:T ratio showed a
similar trend as serum exosomal miR-142-5p (Fig. 7c). The
relationship between exosomal miR-142-5p and K:T ratio
in the serum of CSCC patients was further investigated. As
shown in Fig. 6d, exosomal miR-142-5p level positively
associated with the K:T ratio in the serum of CSCC patients
(r= 0.603, P < 0.001), indicating the potential value of
serum exosomal miR-142-5p for the evaluation of IDO
activity during CSCC progression.
In summary, our results show that CSCC-secreted exo-
somal miR-142-5p down-regulates the lymphatic expres-
sion of ARID2, inhibits DNMT1 recruitment to the IFN-γ
promoter, and enhances IFN-γ transcription by suppressing
promoter methylation, leading to elevated IDO activity to
mediate CD8+ T cell exhaustion (Fig. 7e).
Discussion
Multiple studies have demonstrated the clinical relevance of
tumour-associated LECs and their involvement in malignant
progression [31–33]. While tumour-associated LECs sup-
port the migration of tumour cells, they can enhance Foxp3-
regulatory T cell functions and suppress responses of
effector T cells, as demonstrated from the gain of a phe-
notype similar to that of lymphatic node LECs in mice
[6, 34]. Our clinical data suggest that tumour-associated
LVs helped to modulate anti-tumour immunity and their
levels correlated with poor clinical outcome in CSCC
patients. Thus, tumour-associated LVs are an integral
component of the immunosuppressive TME. However, the
mechanism underlying their function in mediating anti-
tumour immunity is poorly understood.
In a recent study on recurrent or metastatic CSCC, the
objective response rate was only 14.3% after treatment with
anti-PD-1 antibodies for the blockade of immune check-
points despite the selection of patients based on high PD-L1
expression score [35]. These outcomes suggest that addi-
tional immune checkpoint(s) mechanisms may control anti-
tumour immunity. Extensive evidence suggests that IDO is
associated with immune checkpoint(s) in many cancers
[36–38], and our findings reveal the promotion of CD8+ T
cell exhaustion via IDO mediated by CSCC-remodelled
LECs. Although a previous study reported the anti-tumour
activity of IDO+ LECs in vitro [39], the molecular
mechanism leading to lymphatic IDO overexpression in the
TME was not identified.
The immune TME is a dynamic system involving a
complex intercellular crosstalk that develops and maintains
an immune regulatory microenvironment to support tumour
growth [40]. Exchange of cellular materials between cells
through various paracrine and endocrine mechanisms is an
important mean of intercellular crosstalk that may be exe-
cuted by exosomes [25]. miRNAs from cancer-secreted
exosomes are highly versatile regulators of this commu-
nication process [41]. In the present study, we found that
high miR-142-5p expression correlated with peri-tumoural
IDO+ LVs during CSCC progression in humans. The role
of miR-142-5p as a tumour suppressor or oncogene seems
to be cancer type-dependent [11, 12, 42]. Thus, a cancer-
specific mechanism underlying the role of miR-142-5p may
exist. Our observation that miR-142-5p was directly trans-
ferred from tumour cells to LECs via exosomes and up-
regulated lymphatic IDO expression supported our initial
correlative clinical data. In a previous study, we showed
that CSCC-secreted exosomal miRNAs served as inter-
cellular regulators between cancer cells and LECs and
contributed to the remodelling of peri-tumoural LVs for
metastatic spread [43]. Furthermore, high miR-142-5p
expression in serum exosomes was associated with ele-
vated IDO activity in advanced cancer stages. A recent
study by Ferns et al. supported our idea that IDO activity
correlated with poor clinicopathological parameters in
CSCC [44]. Our results showed that aside from
Fig. 6 miR-142-5p-activated HDLECs induce IDO to exhaust
CD8+ T cells. HDLECs pre-treated with indicated exosomes were
cocultured with in vitro-activated CD8+ T cells at a ratio of 1:1 with or
without 100 nM of an IDO inhibitor (BMS-986205). The expression of
CD69 (a), IFN-γ (b), PD-1 (c), and annexin V (d) in CD8+ T cells was
determined by FACS. S/miR-NC exo, Siha/miR-NC exosomes. S/
miR-142 exo, Siha/miR-142-5p exosomes. C/miR-NC exo, Caski/
miR-NC exosomes. C/miR-142 exo, Caski/miR-142-5p exosomes.
Error bars represent the mean ± SD of three independent experiments.
***P < 0.001.
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IDO-mediated anti-tumour immune activity, CSCC malig-
nant progression altered the level of miR-142-5p in serum
exosomes, indicating that serum exosomal miR-142-5p may
discriminate between indolent and aggressive CSCC and
contribute to the development of personalised diagnostic
strategies for patients with different progression risks. We
found that an IDO inhibitor abrogated the ability of LECs
treated with exosomal miR-142-5p to suppress CD8+
T cells. In comparison with an anti-PD-1 treatment alone,
the treatment with IDO inhibitor and anti-PD-1 agent
increased ORR in CSCC [45]. Thus, therapies targeting
miR-142-5p in combination with existing immune therapies
such as IDO and PD-1 inhibitors may serve as compre-
hensive therapeutic approaches for CSCC patients at high
risk of progression.
Numerous genes as direct targets of miR-142-5p have
been identified. For instance, miR-142-5p directly sup-
presses the expression of suppressor of cytokine signal-
ling 1 (SOCS1) to control the programming of
profibrogenic macrophages via the activation of the signal
transducer and activator of transcription (STAT) signal-
ling [46]. Here, we identified a novel target ARID2 as the
most down-regulated protein among the several predicted
targets associated with miR-142-5p. ARID2 was proven
to be a direct target of miR-142-5p by a luciferase reporter
assay. In addition, we found that high ARID2 expression
correlated with low miR-142-5p levels in human CSCC
progression. Members of the ARID family have the ability
to regulate transcription and are involved in cell differ-
entiation and proliferation [47]. ARID2 functions as a
subunit of the polybromo- and BRG1-associated factor or
PBAF (SWI/SNF-B) chromatin remodelling complex,
which facilitates ligand-dependent transcriptional activa-
tion by nuclear receptors [48]. Several studies have
revealed the role of ARID2 as a significant tumour sup-
pressor in many cancer subtypes [49]. Our data suggest
that ARID2 protein level can be reduced in LECs by miR-
142-5p mimics or exosomes containing miR-142-5p.
Fig. 7 Serum exosomal miR-142-5p level correlates with systemic
IDO activity and clinicopathological progression in patients with
CSCC. a Morphology of exosomes isolated and purified from
the serum of CSCC patients and healthy controls. Scale Bar: 50 nm.
b–c miR-142-5p level and K:T ratio were detected in the serum
exosomes of early-stage (FIGO 2018, stages I and II, n= 27) and
advanced-stage (FIGO 2018, stages III and IV, n= 17) CSCC patients
as well as healthy controls (n= 8). d Correlation analysis of exosomal
miR-142-5p and K:T ratio in the serum of CSCC patients and healthy
controls. e Proposed schematic diagram of exosomal miR-142-5p
promoting lymphatic IDO expression to facilitate the immune escape
of cancer cells via CD8+ T cell exhaustion. LECs, lymphatic endo-
thelial cells. miR-142, miR-142-5p. Kyn, kynurenine. Trp, tryptophan.
Error bars represent the mean ± SD of three independent experiments.
**P < 0.01; ***P < 0.001.
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Moreover, overexpression or knockdown of ARID2 could
block or replicate the effects induced by miR-142-5p,
respectively. IFN-γ-activated LECs can directly produce
IDO in vitro [39], prompting us to determine whether
IFN-γ could act as a downstream effector of the miR-142-
5p-ARID2 axis. We found that high levels of miR-142-5p
down-regulated ARID2 expression, leading to the up-
regulation in the expression of IDO mediated by increased
IFN-γ secretion.
Chromatin remodelling molecules often regulate gene
expression by cooperating with epigenetic modulators,
such as the E2F4-RBL2-HDAC1-BRM complex involved
in proline-rich acidic protein 1 (PRAP1) transcriptional
repression [50]. A recent study confirmed the recruitment
of DNMT1 as an epigenetic modulator by ARID2 to
enhance the methylation of gene promoter [29] that led us
to investigate whether the ARID2-DNMT1 complex was
also involved in the regulation of IFN-γ transcription. We
verified the co-occupancy of ARID2 and DNMT1 at the
same region of the IFN-γ promoter. In addition, the
binding of DNMT1 to the IFN-γ promoter resulted in an
increase in DNA methylation and was regulated by
ARID2 expression. These data suggest that DNMT1 was
recruited to the IFN-γ promoter by ARID2 to enhance
promoter methylation.
In conclusion, our data provide evidence for the asso-
ciation of high levels of circulating exosomal miR-142-5p
with increased IDO activity in advanced CSCC. The hor-
izontal transfer of CSCC-secreted exosomal miR-142-5p to
LECs results in the down-regulation of ARID2 expression,
inhibition of DNMT1 recruitment to the IFN-γ promoter,
and enhancement of IFN-γ transcription via the suppression
of promoter demethylation, eventually elevating IDO
activity for CD8+ T cell exhaustion. The newly identified
miR-142-5p–ARID2–DNMT1–IFN-γ–IDO axis in LECs
appears to be a critical molecular mechanism underlying
CSCC progression and may serve as a novel diagnostic and
therapeutic target for CSCC patients at high risk of
progression.
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